COPD Exacerbation: Clinical Trials

3 trials for COPD Exacerbation, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 terminated. 3 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 43Terminated 3

Follow COPD Exacerbation: new trials by email Literature Review of COPD Exacerbation trials Research Report on COPD Exacerbation

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
The Effects of Enoximone in Acute Exacerbation COPD
Enoximone - COPD Exacerbation, Enoximone
Phase 4TerminatedRijnstate Hospital32020-05-122022-01-13
Comparing Mortality for Low vs High Peripheral Oxygen Saturation in COPD-patients With Acute Exacerbation
Oxygen gas - COPD Exacerbation, Chronic Obstructive Pulmonary Disease Exacerbation
Phase 4TerminatedEsbjerg Hospital - University Hospital of Southern Denmark232020-02-032026-03-11
Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)
Nebulizers, Dry Powder Inhaler, Brovana - COPD, COPD Exacerbation
Phase 4TerminatedWake Forest University Health Sciences402017-10-032021-06-22

Narrower conditions

Pulmonary Disease, Chronic Obstructive (2)

Broader conditions

Chronic Disease (2)  ·  Disease Attributes (2)  ·  Lung Diseases (2)  ·  Lung Diseases, Obstructive (2)  ·  Pathologic Processes (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Respiratory Tract Diseases (2)

Interventions

Budesonide (1)  ·  Dry Powder Inhalers (1)  ·  Enoximone (1)  ·  Fluticasone-Salmeterol Drug Combination (1)  ·  Formoterol Fumarate (1)  ·  Ipratropium (1)  ·  Nebulizers and Vaporizers (1)  ·  nitrox (1)

Sponsors

Esbjerg Hospital - University Hospital of Southern Denmark (1)  ·  Rijnstate Hospital (1)  ·  Wake Forest University Health Sciences (1)

Countries

Denmark (1)  ·  Netherlands (1)  ·  United States (1)

Top investigators

Jill A Ohar, MD, FCCP (1)  ·  Peter Hallas, MD (1)  ·  Simon Thorgaard-Rasmussen, MD (1)  ·  Sune Laugesen, MD (1)

NIH funding

2019 (1)